Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) Belonging to the Medical sector which declined -0.15% and closed its last trading session at $13.69.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/1/2016. Currently, the stock has a 1 Year Price Target of $11.63.
The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.2 and 2.2 respectively.
Ariad Pharmaceuticals Inc. on 6/30/2016 reported its EPS as $0.56 with the analysts projecting the EPS of the stock as $-0.11. The company beat the analyst EPS Estimate with the difference of $0.67. This shows a surprise factor of 609.1%.
Many analysts have provided their estimated foresights on Ariad Pharmaceuticals Inc. Earnings, with 9 analysts believing the company would generate an Average Estimate of $-0.2. Whereas they predicted High and Low Earnings Estimate as $-0.18 and $-0.23 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.29.
Analysts are also projecting an Average Revenue Estimate for Ariad Pharmaceuticals Inc. as $39.92 Million in the Current Quarter. This estimate is provided by 9 analysts. The High Revenue estimate is predicted as 44 Million, while the Low Revenue Estimate prediction stands at 36 Million. The company’s last year sales total was 29.07 Million.
For the Current Quarter, the growth estimate for Ariad Pharmaceuticals Inc. is 31%, while for the Next Quarter the stock growth estimate is 43.8%. In the past 5 years, the stock showed growth of 0% per annum. While for the next 5 years, the growth estimate is 30%.
The Company got Initiated by Leerink Partners on 26-Sep-16 to Outperform.
Insider Trades for Ariad Pharmaceuticals Inc. show that the latest trade was made on 27 Sep 2016 where Clackson (Timothy P), the Officer completed a transaction type “Sell” in which 8750 shares were traded at a price of $13.98.
6 Insider Sales transactions were made totaling 225588 shares traded.
8 analysts projected Price Targets for Ariad Pharmaceuticals Inc. The analysts believe that the company stock price could grow as high as $20. The Low Price target projection by analysts is $8 and the Mean Price Target is $11.63.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) has the market capitalization of $2.64 Billion. The company rocked its 52-Week High of $14.26 on Sep 28, 2016 and touched its 52-Week Low of $4.37 on Feb 11, 2016. The stock has Return on Assets (ROA) of -10.5 percent. Return on Equity (ROE) stands at 68.8% and Return on Investment (ROI) of -62.9 percent.
The stock is currently showing YTD performance of 119.04 Percent. The company has Beta Value of 1.8 and ATR value of 0.5. The Weekly and Monthly Volatility stands at 4.08% and 4.29%.
Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.